Longevity Vision Fund
Overview
Longevity Vision Fund is a venture capital firm that invests in technologies with the potential to disrupt life sciences and healthcare to help people live longer and healthier lives.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Valo Health | Oct 2022 | Series C | Co-investor |
| Insilico Medicine | Sep 2019 | Series B | - |
| Biolinq | Nov 2021 | Series B | Co-investor |
| Tessera Therapeutics | Apr 2022 | Series C | Co-investor |
| LyGenesis | Dec 2020 | Convertible Debt | Lead |
For institutional investors. Book with your work email.
Key People
Sergey Young
Founder
Sourav Sinha
General Partner & Head Of Strategy
Emily Rhen
Investor Relations
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Longevity Vision Fund based?
Longevity Vision Fund is headquartered in New York City, New York, United States.
When was Longevity Vision Fund founded?
Longevity Vision Fund was founded in 2019.
How many portfolio companies does Longevity Vision Fund have?
Longevity Vision Fund has 7 portfolio companies in Caplight's dataset.
What are some companies in Longevity Vision Fund's portfolio?
Portfolio companies visible on Caplight include Valo Health, Insilico Medicine, Biolinq, Tessera Therapeutics, LyGenesis.
What was Longevity Vision Fund's most recent investment shown here?
Longevity Vision Fund's most recent investment in this portfolio sample was in Valo Health in 2022.
What sectors does Longevity Vision Fund focus on?
Longevity Vision Fund focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure.
What company stages does Longevity Vision Fund focus on?
Stage focus information for Longevity Vision Fund is not publicly available.
What is Longevity Vision Fund's AUM?
Longevity Vision Fund's assets under management are estimated between $100.0M and $100.0M.